Acute graft versus host disease
MONDO:0020546A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.
Also known as: GVHD, acute, acute graft vs. host disease, fulminant graft versus host disease, graft versus host disease, acute, acute GVHD
90 clinical trials for this condition and its sub-types, 86 tagged with Acute graft versus host disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a lung drug stop transplant rejection? new trial tests Alpha-1 antitrypsin for GVHD
Disease control Stopped earlyThis study tested whether a drug called alpha-1 antitrypsin (AAT) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. The trial enrolled 222 participants and compa…
Phase 2/3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill tested for severe transplant complication
Disease control Stopped earlyThis study tested a new drug, TQ05105, in 13 people who had severe graft-versus-host disease (aGVHD) after a stem cell transplant and did not respond to steroids. The goal was to see if the drug is safe and can help control the disease. The study was stopped early, so results are…
Phase 1/2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Placenta cell therapy shows promise for tough transplant complication
Disease control Stopped earlyThis trial tested a treatment made from placenta cells (called decidua stroma cells) in 12 adults who had severe graft-versus-host disease (GVHD) after a stem cell transplant and did not respond to steroids. Patients received two doses of the cells or the best available standard …
Phase 2 • Sponsor: Mats Remberger • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental combo for Graft-Versus-Host disease fails to enroll
Disease control Stopped earlyThis study tested a mix of drugs (cyclophosphamide, sirolimus, low-dose IL-2, and azacitidine) to treat severe graft-versus-host disease that didn't respond to steroids. Only 3 patients were enrolled before the trial was stopped early. The goal was to see if the treatment could c…
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo aims to tame deadly transplant complication with fewer steroids
Disease control Stopped earlyThis study tested a combination of three drugs (ruxolitinib, uhCG/EGF, and steroids) in 10 people with a severe form of acute graft-versus-host disease (aGVHD), a complication that can occur after a stem cell transplant. The goal was to find the lowest effective steroid dose to r…
Phase 1/2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cell therapy aims to stop transplant complications in blood cancer patients
Disease control Stopped earlyThis early-phase study tested whether a special type of cell (interferon gamma-primed mesenchymal stromal cells) could be safely given to prevent graft-versus-host disease, a common and serious complication after bone marrow transplant. Only 4 patients with acute leukemia or myel…
Phase 1 • Sponsor: Edwin Horwitz • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Pediatric GVHD drug combo trial halted early after just 2 kids enrolled
Disease control Stopped earlyThis study tested a drug called itacitinib combined with steroids to treat acute graft-versus-host disease (aGVHD) in children. aGVHD is a serious complication where donor immune cells attack the child's body after a stem cell transplant. The trial was stopped early after enrolli…
Phase 1/2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental drug targets gut damage in transplant patients
Disease control Stopped earlyThis Phase 2 trial tested apraglutide, a drug that helps repair the gut lining, in 31 people with severe gastrointestinal graft-versus-host disease (GVHD) after a stem cell transplant. Participants had GVHD that did not respond to steroids. The study aimed to see if apraglutide i…
Phase 2 • Sponsor: VectivBio AG • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New antibody treatment aims to shield transplant patients from dangerous virus
Disease control Stopped earlyThis study tested a drug called Cytotect, which contains antibodies against the CMV virus, to prevent CMV infection in people who had a stem cell transplant and developed graft-versus-host disease (GVHD). These patients are at high risk for CMV, and current antiviral drugs often …
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Blood pressure drug tested to prevent transplant complication
Prevention Stopped earlyThis pilot study tested the blood pressure drug telmisartan (Micardis) to prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. The trial aimed to enroll 60 participants but was terminated early with 32. Researchers tracked s…
Sponsor: Hackensack Meridian Health • Aim: Prevention
Last updated Jun 27, 2026 12:03 UTC